APA (7th ed.) Citation

N, R., R, E. M., T, M., D, A., A, D., N, P., . . . U, G. (2024). Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. Cancer research communications, 4(2), 337. https://doi.org/10.1158/2767-9764.CRC-23-0321

Chicago Style (17th ed.) Citation

N, Roper, et al. "Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer." Cancer Research Communications 4, no. 2 (2024): 337. https://doi.org/10.1158/2767-9764.CRC-23-0321.

MLA (9th ed.) Citation

N, Roper, et al. "Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer." Cancer Research Communications, vol. 4, no. 2, 2024, p. 337, https://doi.org/10.1158/2767-9764.CRC-23-0321.